COO Surges As Cooper Companies Extends Earnings Beat Streak

The Cooper Companies Inc. stocks have been trading up by 8.47 percent following strong earnings and upbeat guidance.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading COO

JOIN 50,000+ ACTIVE TRADERS

What Traders Need To Know

Q2 2026 revenue hit $1.08B, up 8% and ahead of estimates, with non-GAAP EPS up 26% to $1.21, marking a record quarter and tenth straight earnings beat for The Cooper Companies Inc.
GAAP EPS was a loss of $0.40 due to a $271.6M litigation charge from the 2023 CooperSurgical fertility media recall, though most related claims are reportedly resolved, reducing legal overhang.
Management reaffirmed 2026 non-GAAP EPS guidance of $4.58–$4.66, slightly cut revenue to $4.29–$4.32B, and reiterated a $2.2B-plus free cash flow target for 2026–2028.
Shares of COO jumped roughly 7–8.6% to the mid-$60s, leading the S&P 500 after the earnings beat and updated outlook, with strong buying interest on the day.
Major banks cut price targets into the mid-$80s but kept Buy/Outperform ratings, citing de-risked guidance, operating leverage, and potential value from strategic options around the CooperSurgical business.

Weekly Update Jun 01 – Jun 05, 2026: On Saturday, June 06, 2026 The Cooper Companies Inc. stock [NASDAQ: COO] is trending up by 8.47%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Cooper Companies (COO) sits as a premium, scale player in contact lenses and women’s health, with structurally attractive 65% gross margin and high-20s EBITDA margin, but only mid‑single‑digit ROIC and ROE reflecting heavy goodwill and intangible assets. Revenue growth (7–11% 3–5yr CAGR) is solid versus medtech peers, and leverage is manageable with 0.3x debt/equity and 1.5x leverage. A near‑40x P/E and 3.8x sales embed a quality premium despite temporary GAAP losses from litigation charges.

Technically, COO has shifted from base‑building to a nascent uptrend: the rapid move from ~59 to ~67 on strong post‑earnings volume marks a clean breakout, with 65 now the first key support level. The clustered 5‑minute candles near 67–68 indicate emerging resistance where supply appears. Dominant trend is short‑term bullish within a still‑developing intermediate base. A defined, actionable level: buy pullbacks toward 65–66 with a stop below 62, targeting a retest of the low‑70s.

More Breaking News

Fundamentally, COO’s Q2 beat, record non‑GAAP EPS, and resolution of most CSI litigation remove a major overhang and compare favorably versus broader Healthcare and Equipment peers, where many are guiding cautiously. While sell‑side targets have been cut to the mid‑80s, consensus still implies substantial upside from the mid‑60s. A potential CSI divestiture would sharpen focus on the higher‑quality CVI franchise and likely re‑rate the equity. Tactical levels: support 65, resistance 72, 12‑month base‑case target 80.

Quick Financial Overview

The Cooper Companies Inc. delivered a strong fiscal Q2 2026 print, with revenue of $1.08B up 8% year over year and about $30M ahead of consensus. Non-GAAP EPS of $1.21 rose 26% and beat expectations, while non-GAAP operating margin expanded to 27%, signaling solid cost control. GAAP EPS of -$0.40 reflected a $271.6M litigation charge from the CooperSurgical fertility media recall, so the headline loss is mostly about a one-time legal clean-up, not collapsing operations.

From a fundamental angle, COO runs at a healthy 65.4% gross margin and 16.9% EBIT margin, with revenue growing in the high single digits over recent years. Return metrics like roughly 4–6% ROE and ROA show moderate efficiency, while balance sheet leverage looks manageable with total debt to equity around 0.3 and interest coverage above 11x. Free cash flow of about $96.4M in the latest quarter and management’s target of more than $2.2B over 2026–2028 underline a cash-generative profile.

On the tape, COO moved from the high-$50s to above $67 over a few sessions, with the weekly high at 67.98 and a recent close near 67.27. That 10–12% push, including a 6.9% gap toward $66.27 and a strong intraday candle from roughly 65 to 67.34, confirms aggressive dip buying after the print. With consensus targets in the mid-$80s to mid-$90s and a mean target around $90.33 against a prior price near 61.46, traders are clearly re-rating the name but still see room above current levels.

Conclusion

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!